Global Drug Survey (GDS) 2021. Key findings report

A. R. WINSTOCK ; L. J. MAIER ; A. ZHUPARRIS ; E. DAVIES ; C. PULJEVIC ; K. P. C. KUYPERS ; J. A. FERRIS ; M. J. BARRATT | 2021
Rapport

Data collection period: GDS2021 ran between December 2020 and March 2021. Sample characteristics Global Drug Survey 2021 (GDS2021): Data from over 32,000 people from over 20 countries were used in the preparation of this report. 62% were cisg[...]

Plus d'info

Ajouter à la sélection

Lien externe

'Money up in smoke': The financial benefits of smoking cessation may be more motivating to people who are homeless than potential health gains

C. PULJEVIC ; A. SNOSWELL ; L. RIVAS ; M. M. ALI ; W. DE GREEF ; J. FERRIS ; C. GARTNER | 2021
Dans Drug and Alcohol Review (Vol.40, n°7, November 2021) Article : Périodique

INTRODUCTION: High rates of tobacco smoking among people who are homeless or living in temporary accommodation exacerbate poor health outcomes and financial disadvantage. There is limited research on this population's perceptions of smoking cess[...]

Plus d'info

Ajouter à la sélection

Lien externe

Shifts in cannabis use at the onset of the COVID-19 pandemic among Global Drug Survey respondents from 13 countries

C. PULJEVIC ; A. COSSART ; E. L. DAVIES ; M. J. BARRATT ; L. J. MAIER ; M. JAUFFRET-ROUSTIDE ; A. R. WINSTOCK ; J. A. FERRIS | 2023
Dans Drugs, Habits and Social Policy (Vol.24, n°3, 2023) Article : Périodique

Purpose: The COVID-19 pandemic likely impacted cannabis distribution, access and usage worldwide. This study aims to describe self-reported changes in cannabis use and related outcomes following COVID-19-related restrictions among an internation[...]

Plus d'info

Ajouter à la sélection

Lien externe

Systematic review and meta-analyses of cytisine to support tobacco cessation

C. PULJEVIC ; D. STJEPANOVIC ; I. MECIAR ; H. KANG ; G. CHAN ; K. MORPHETT ; H. BENDOTTI ; G. KUNWAR ; C. GARTNER | 2024
Dans Addiction (Vol.119, n°10, October 2024) Article : Périodique

BACKGROUND AND AIMS: Cytisine (also known as cytisinicline) is a low-cost partial agonist of nicotinic acetylcholine receptors used to assist tobacco cessation. We aimed to review the effectiveness of cytisine for tobacco cessation and the effec[...]

Plus d'info

Ajouter à la sélection

Lien externe